Literature DB >> 16215303

Non-invasive diagnostic tests for bladder cancer: a review of the literature.

PierFrancesco Bassi1, Vincenzo De Marco, Antonello De Lisa, Mariangela Mancini, Francesco Pinto, Rossella Bertoloni, Fabrizio Longo.   

Abstract

Transitional cell carcinoma of the bladder is the second most common malignancy of the genitourinary tract. Cystoscopy and urine cytology are the traditional most used techniques for diagnosis and surveillance of superficial bladder cancer. Urine cytology is specific for diagnosis of bladder cancer but sensitivity results not high, particularly in low-grade disease. Voided urine can be easily obtained and therefore additional diagnostic urine tests would be ideal for screening or follow-up of transitional cell carcinoma. A number of studies have focused on the evaluation of urinary markers that hold promise as non-invasive adjuncts to conventional diagnostic or surveillance techniques. In this review we discuss several new urinary markers (test for bladder tumor antigen, NMP22, fibrin degradation products, telomerase, fluorescence in situ hybridization test, flow cytometry) and their role in detection and follow-up of bladder cancer. Most of these markers have higher sensitivity than urine cytology, but voided urine cytology has the highest specificity. Copyright (c) 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16215303     DOI: 10.1159/000087792

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  9 in total

1.  A pilot study of urinary microRNA as a biomarker for urothelial cancer.

Authors:  Jaime Snowdon; Sandy Boag; Harriet Feilotter; Jason Izard; D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2013 Jan-Feb       Impact factor: 1.862

Review 2.  Hexyl aminolevulinate: in the detection of bladder cancer.

Authors:  James E Frampton; Greg L Plosker
Journal:  Drugs       Date:  2006       Impact factor: 9.546

3.  Quantitation of rare circulating tumor cells by folate receptor α ligand-targeted PCR in bladder transitional cell carcinoma and its potential diagnostic significance.

Authors:  Fuming Qi; Yuchen Liu; Rongchang Zhao; Xiangjun Zou; Lei Zhang; Jiaqiang Li; Yongqiang Wang; Feiyang Li; Xiaowen Zou; Ye Xia; Xuliang Wang; Li Xing; Cailing Li; Jingxiao Lu; Junlong Tang; Fangjian Zhou; Chunxiao Liu; Yaoting Gui; Zhiming Cai; Xiaojuan Sun
Journal:  Tumour Biol       Date:  2014-04-27

4.  Usefulness of the NMP22BladderChek Test for Screening and Follow-up of Bladder Cancer.

Authors:  Hwa Sub Choi; Sang Ik Lee; Dong Jun Kim; Tae Yoong Jeong
Journal:  Korean J Urol       Date:  2010-02-18

5.  Non-invasive prediction of recurrence in bladder cancer by detecting somatic TERT promoter mutations in urine.

Authors:  Françoise Descotes; Norelyakin Kara; Myriam Decaussin-Petrucci; Eric Piaton; Florence Geiguer; Claire Rodriguez-Lafrasse; Jean E Terrier; Jonathan Lopez; Alain Ruffion
Journal:  Br J Cancer       Date:  2017-07-06       Impact factor: 7.640

Review 6.  MicroRNAs in biofluids are novel tools for bladder cancer screening.

Authors:  Xiaobing Liu; Xin Liu; Yuqi Wu; Qingjian Wu; Qingqing Wang; Zhenxing Yang; Longkun Li
Journal:  Oncotarget       Date:  2017-05-09

7.  Epirubicin suppresses proliferative and metastatic potential by downregulating transforming growth factor-β-induced expression in urothelial carcinoma.

Authors:  Donghao Shang; Bo Song; Yuting Liu
Journal:  Cancer Sci       Date:  2018-02-20       Impact factor: 6.716

8.  The role of collecting bladder wash fluid before biopsy procedure to help the cytological diagnosis of residual tumor.

Authors:  Aydan Kiliçarslan; Nuran Süngü; Serdar Balci; Erdem Canda; Serkan Altinova; Gülnur Güler
Journal:  J Cytol       Date:  2015 Apr-Jun       Impact factor: 1.000

9.  SFRP Tumour Suppressor Genes Are Potential Plasma-Based Epigenetic Biomarkers for Malignant Pleural Mesothelioma.

Authors:  Yuen Yee Cheng; Ellie Mok; Sarah Tan; Catherine Leygo; Chris McLaughlin; A M George; Glen Reid
Journal:  Dis Markers       Date:  2017-12-13       Impact factor: 3.434

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.